Amgen recently announced top-line results from a phase 3 clinical trial that sought to evaluate the safety and efficacy of its proposed infliximab biosimilar, ABP 710, compared with the reference product (Remicade) in patients with moderate-to-severe rheumatoid arthritis (RA).
Amgen recently announced top-line results from a phase 3 clinical trial that sought to evaluate the safety and efficacy of its proposed infliximab biosimilar, ABP 710, compared with the reference product (Remicade) in patients with moderate-to-severe rheumatoid arthritis (RA).
The randomized double-blind study enrolled 558 and randomized (1:1) 558 patients with RA to receive either ABP 710 or reference infliximab at a dose of 3 mg/kg infused on day 1, at weeks 2 and 6, and every 8 weeks thereafter. The ABP 710 arm, as well as the reference infliximab arm, were equally comprised of 279 patients.
The primary end point of the study was achieving 20% or greater improvement as defined by the American College of Rheumatology criteria (ACR20) at week 22. Secondary endpoints included achieving ACR50, ACR70, and disease activity score 28-joint count C reactive protein (DAS28-CRP).
Researchers confirmed the noninferiority of ABP 710 compared with infliximab, but “could not rule out superiority based on its primary efficacy endpoint,” according to the news release. Notably, the DAS28-CRP difference in mean change from the baseline was close to 0, at —0.01 (95% CI, –0.20 to 0.17). In addition, the safety profile and immunogenicity were comparable between ABP 710 and the originator.
“We believe this study confirms no clinically meaningful differences between ABP 710 and [reference] infliximab. Biosimilars are approved based on the analytical, nonclinical, and clinical data, and we believe that the totality of the evidence we’ve generated supports ABP 710 as highly similar to the reference product,” said Sean Harper, MD, executive vice president of research and development at Amgen in a statement.
Amgen is also working on the development of a number of other biosimilar products, including ABP 494, biosimilar cetuximab; ABP 798, biosimilar rituximab; ABP 959, biosimilar eculizumab, and Kanjinti, a trastuzumab biosimilar that was authorized for marketing in Europe in May 2018, 1 day after it was announced that the FDA had issued a Complete Response Letter for the same product.
Global Biosimilar Market Projected to Reach $1.3 Trillion by 2032
April 11th 2024The global biosimilar market is projected to surge from $25.1 billion in 2022 to approximately $1.3 trillion by 2032, with a compound annual growth rate of 17.6%, driven mainly by the increasing prevalence of cancer and the cost-effectiveness of biosimilars, as outlined in a report by Towards Healthcare.
Exploring the Biosimilar Horizon: Julie Reed's Predictions for 2024
February 18th 2024On this episode of Not So Different, Julie Reed, executive director of the Biosimilars Forum, returns to discuss her predictions for the biosimilar industry for 2024 and beyond as well as the impact that the Forum's 4 new members will have on the organization's mission.
Study: More Biosimilar Competition Is Not Lowering Patient OOP Costs
March 29th 2024Despite more biosimilars entering the market and generating significant savings for payers and health care systems, these savings are not resulting in lower out-of-pocket (OOP) costs for patients, according to a recent study.
Biosimilar Business Roundup for October 2023—Podcast Edition
November 5th 2023On this episode, we discuss the biggest news to come out of October 2023, including 3 regulatory approvals, 2 complete response letters, and new data and industry insights that have the potential to impact the entire US biosimilar industry.
Coherus Biosciences Cites Biosimilars as Main Drivers of 2023 Revenue Growth
March 14th 2024In its earnings report for the fourth quarter and full year of 2023, Coherus Biosciences detailed its rising revenue growth, which it partly attributed to increased sales for its pegfilgrastim and ranibizumab biosimilars.